Health · 9 views
FDA OKs First Drug for Primary Membranous Nephropathy
Story intelligence
Coverage Single outlet Single-outlet story
Views 9 Community interest
Brief read Under 1 min brief 26 words
Summary
(MedPage Today) -- The FDA has once again expanded the label for the B-cell depleter obinutuzumab (Gazyva), this time to include treatment of primary membranous nephropathy.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Liver cells activate scarring-linked genes in stiff surroundings but favor repair signals in softer conditionsContinue reading
- First results published from the largest brain atlas ever createdContinue reading
- Brain scans reveal two regions that shrink before the hippocampus in Alzheimer'sContinue reading
- The U.S. Just Lost Its Measles Elimination Status. Here's How to Get It Back.Continue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow